According to GuruFocus Insider Data, the largest CFO sells during the past week were: Qualcomm Inc., RailAmerica Inc., Arena Pharmaceuticals Inc., Actuant Corporation, Quest Diagnostics Inc., and Microsemi Corporation.
Qualcomm Inc. develops and delivers innovative digital wireless communications products and services based on the company's CDMA digital technology. Qualcomm has a market cap of $106.4 billion; its shares were traded at around $62.65 with a P/E ratio of 19.8 and P/S ratio of 7.1. The dividend yield of Qualcomm, Inc. stocks is 1.6%. Qualcomm, Inc. had an annual average earnings growth of 18.2% over the past 10 years. GuruFocus rated Qualcomm, Inc. a business predictability rank of 3.5-star.
For its third quarter of 2012, Qualcomm Inc. generated GAAP net revenues of $4.6 billion, representing an increase of 28% year-after-year. GAAP net income was $1.21 billion, up 17 percent from the prior year's quarter, and diluted EPS was $0.69, up 13% over the same quarter last year. Operating cash flow was $922 million, down 27% from last year, and representing 20% of total revenues. In this quarter, Qualcomm paid $0.25 per share in dividends, and repurchased 6.6 million shares of its stock.
Chairman and CEO, Paul E. Jacobs sold 30,000 shares of QCOM stock on 10/01/2012 at the average price of $62.73. Vice Chairman Steven R Altman and other insiders also sold shares of QCOM stock over the past week.
RailAmerica, Inc. primarily engages in the ownership and operation of short line and regional freight railroads in North America, with a P/E ratio of 23.5 and a P/S ratio of 2.5.
RailAmerica Inc. has released its second quarter 2012 results. Revenues increased by 12% over the same quarter in 2011. Net income was $11.4 million ($0.23 per diluted share), compared to income of $8.7 million ($0.17 per share) compared to the prior year's same quarter.
President and CEO John Giles sold 509,256 shares of RA stock on 10/01/2012 at the average price of $27.50. Senior Vice President and General Counsel Scott G. Williams,10% owner of Fortress Investment Group, LLC, and multiple other insiders also sold shares of RA stock.
Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena has a market cap of $1.81 billion; its shares were traded at around $8.64 with a P/S ratio of 142. The company had an annual average earnings growth of 0.7% over the past 10 years.
Arena reported second quarter 2012 revenues of $22 million, as compared to $3.3 million for the prior year's quarter. The increase in revenue was largely due to a $20 million milestone payment earned under a marketing and supply agreement with global pharmaceutical company, Eisai.
Actuant, headquartered in Milwaukee, Wisconsin, is a diversified industrial company with operations in 15 countries. Actuant Corporation has a market cap of $2.09 billion; its shares were traded at around $28.65 with a P/E ratio of 13.8 and a P/S ratio of 1.3. The dividend yield of Actuant stocks is 0.1% and the company had an annual average earnings growth of 3.9% over the past 10 years.
Actuant Corporation has released its fourth quarter 2012 results. For this quarter, ending August 31, 2012, Actuant reported diluted EPS of $0.55 – an increase of 10% year over year. Core sales grew 3% in the fourth quarter 2012.
Quest Diagnostics Inc., is the provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. Quest Diagnostics has a market cap of $10.07 billion; its shares were traded at around $64.17 with a P/E ratio of 13.6 and P/S ratio of 1.3. The dividend yield of Quest Diagnostics stocks is 1.1%, and the company had an annual average earnings growth of 11.4% over the past 10 years. GuruFocus rated Quest Diagnostics Inc. a business predictability rank of 3.5 stars.
Microsemi Corp. is a designer, manufacturer and marketer of analog, mixed-signal and discrete semiconductors. Microsemi Corporation has a market cap of $1.79 billion; its shares were traded at around $19 with a P/E ratio of 12.3 and a P/S ratio of 2.1, and the company had an annual average earnings growth of 16.3% over the past 10 years.
Microsemi Corporation has released its second quarter 2012 results ending July 1, 2012. Net sales for this quarter increased 20% year over year to $259.2 million. GAAP net income was $8.1 million (diluted EPS of $0.09), and operating cash flow was $54.7 million.
President, CEO and Director James J. Peterson sold 80,862 shares of MSCC stock on 10/01/2012 at the average price of 19.93. Multiple other insiders also sold shares of MSCC stock during the past week.
For the complete list of stocks that Sold by their CFOs, go to: Insider Buys.
Qualcomm Inc. (QCOM, Financial): Executive Vice President and CFO William E. Keitel Sold 186,206 Shares
Executive Vice President and CFO, William E. Keitel, sold 186,206 shares of QCOM stock on 10/01/2012 at the average price of $62.49. Keitel owns at least 9,194 shares after this. The price of the stock has increased by 0.26% since.Qualcomm Inc. develops and delivers innovative digital wireless communications products and services based on the company's CDMA digital technology. Qualcomm has a market cap of $106.4 billion; its shares were traded at around $62.65 with a P/E ratio of 19.8 and P/S ratio of 7.1. The dividend yield of Qualcomm, Inc. stocks is 1.6%. Qualcomm, Inc. had an annual average earnings growth of 18.2% over the past 10 years. GuruFocus rated Qualcomm, Inc. a business predictability rank of 3.5-star.
For its third quarter of 2012, Qualcomm Inc. generated GAAP net revenues of $4.6 billion, representing an increase of 28% year-after-year. GAAP net income was $1.21 billion, up 17 percent from the prior year's quarter, and diluted EPS was $0.69, up 13% over the same quarter last year. Operating cash flow was $922 million, down 27% from last year, and representing 20% of total revenues. In this quarter, Qualcomm paid $0.25 per share in dividends, and repurchased 6.6 million shares of its stock.
Chairman and CEO, Paul E. Jacobs sold 30,000 shares of QCOM stock on 10/01/2012 at the average price of $62.73. Vice Chairman Steven R Altman and other insiders also sold shares of QCOM stock over the past week.
RailAmerica Inc. (RA, Financial): Senior Vice President and CFO B. Clyde Preslar Sold 114,527 Shares
Senior Vice President and CFO, B. Clyde Preslar sold 114,527 shares of RA stock on 10/01/2012 at the average price of $27.50.RailAmerica, Inc. primarily engages in the ownership and operation of short line and regional freight railroads in North America, with a P/E ratio of 23.5 and a P/S ratio of 2.5.
RailAmerica Inc. has released its second quarter 2012 results. Revenues increased by 12% over the same quarter in 2011. Net income was $11.4 million ($0.23 per diluted share), compared to income of $8.7 million ($0.17 per share) compared to the prior year's same quarter.
President and CEO John Giles sold 509,256 shares of RA stock on 10/01/2012 at the average price of $27.50. Senior Vice President and General Counsel Scott G. Williams,10% owner of Fortress Investment Group, LLC, and multiple other insiders also sold shares of RA stock.
Arena Pharmaceuticals Inc. (ARNA, Financial): Senior Vice President, of Finance and CFO Robert Hoffman Sold 50,000 Shares
Senior Vice President of Finance and CFO Robert Hoffman sold 50,000 shares of ARNA stock on 10/01/2012 at the average price of $8.32. Robert Hoffman owns at least 3,382 shares after this. The price of the stock has increased by 3.85% since.Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena has a market cap of $1.81 billion; its shares were traded at around $8.64 with a P/S ratio of 142. The company had an annual average earnings growth of 0.7% over the past 10 years.
Arena reported second quarter 2012 revenues of $22 million, as compared to $3.3 million for the prior year's quarter. The increase in revenue was largely due to a $20 million milestone payment earned under a marketing and supply agreement with global pharmaceutical company, Eisai.
Actuant Corporation (ATU, Financial): Executive Vice President and CFO Andrew Lampereur Sold 48,000 Shares
Executive Vice President and CFO, Andrew Lampereur sold 48,000 shares of ATU stock on 10/02/2012 at the average price of $28.65. Andrew Lampereur owns at least 264,203 shares after sell. The price of the stock has not decreased since.Actuant, headquartered in Milwaukee, Wisconsin, is a diversified industrial company with operations in 15 countries. Actuant Corporation has a market cap of $2.09 billion; its shares were traded at around $28.65 with a P/E ratio of 13.8 and a P/S ratio of 1.3. The dividend yield of Actuant stocks is 0.1% and the company had an annual average earnings growth of 3.9% over the past 10 years.
Actuant Corporation has released its fourth quarter 2012 results. For this quarter, ending August 31, 2012, Actuant reported diluted EPS of $0.55 – an increase of 10% year over year. Core sales grew 3% in the fourth quarter 2012.
Quest Diagnostics Inc. (DGX, Financial): Senior Vice President and CFO Robert Hagemann Sold 46,667 Shares
Senior Vice President and CFO Robert Hagemann sold 46,667 shares of DGX stock on 10/03/2012 at the average price of $64. Robert Hagemann owns at least 156,384 shares after this. The price of the stock has increased by 0.27% since.Quest Diagnostics Inc., is the provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. Quest Diagnostics has a market cap of $10.07 billion; its shares were traded at around $64.17 with a P/E ratio of 13.6 and P/S ratio of 1.3. The dividend yield of Quest Diagnostics stocks is 1.1%, and the company had an annual average earnings growth of 11.4% over the past 10 years. GuruFocus rated Quest Diagnostics Inc. a business predictability rank of 3.5 stars.
Microsemi Corporation (MSCC, Financial): Executive Vice President and CFO John W. Hohener Sold 41,000 Shares
Executive Vice President and CFO John W. Hohener sold 41,000 shares of MSCC stock on 10/01/2012 at the average price of $20. John W. Hohener owns at least 72,003 shares after this. The price of the stock has decreased by 5% since.Microsemi Corp. is a designer, manufacturer and marketer of analog, mixed-signal and discrete semiconductors. Microsemi Corporation has a market cap of $1.79 billion; its shares were traded at around $19 with a P/E ratio of 12.3 and a P/S ratio of 2.1, and the company had an annual average earnings growth of 16.3% over the past 10 years.
Microsemi Corporation has released its second quarter 2012 results ending July 1, 2012. Net sales for this quarter increased 20% year over year to $259.2 million. GAAP net income was $8.1 million (diluted EPS of $0.09), and operating cash flow was $54.7 million.
President, CEO and Director James J. Peterson sold 80,862 shares of MSCC stock on 10/01/2012 at the average price of 19.93. Multiple other insiders also sold shares of MSCC stock during the past week.
For the complete list of stocks that Sold by their CFOs, go to: Insider Buys.
